In a young woman taking norethisterone for menorrhagia who presents with acute severe headache, vomiting, seizures or focal neurological deficits and has pro‑thrombotic risk factors (e.g., polycystic ovary syndrome, hyperhomocysteinemia, inherited thrombophilia, smoking, obesity, immobilisation), how should cortical venous sinus thrombosis be diagnosed and managed?

Norethisterone and Cortical Venous Thrombosis: Diagnosis and Management

Immediate Clinical Action

In a young woman taking norethisterone who presents with acute severe headache, vomiting, seizures, or focal neurological deficits—especially with pro-thrombotic risk factors like PCOS, hyperhomocysteinemia, or thrombophilia—immediately obtain urgent MRI with MR venography (or CT venography if MRI unavailable) to diagnose cerebral venous sinus thrombosis, and start therapeutic anticoagulation without delay, even if hemorrhagic transformation is present on imaging. 1, 2

Understanding the Risk Context

Norethisterone and Thrombotic Risk

• Progestin-only preparations (including norethisterone) generally do NOT increase venous thromboembolism risk in most women, unlike combined estrogen-containing contraceptives. 3

• However, case reports document CVST occurring with norethisterone use when multiple prothrombotic factors coexist, particularly in women with PCOS and hyperhomocysteinemia. 4

• The combination of norethisterone with underlying thrombophilia dramatically amplifies risk beyond either factor alone, creating a synergistic prothrombotic state. 5, 4

Key Risk Factor Synergy in Your Patient

Your patient has multiple compounding risks:

• PCOS itself is a prothrombotic condition that increases baseline thrombotic risk. 1, 3
• Hyperhomocysteinemia carries strong evidence for CVST causation (meets biological plausibility and temporality criteria). 1
• Inherited thrombophilias (protein C/S deficiency, Factor V Leiden, prothrombin G20210A) confer 11-fold increased CVST risk. 1, 5
• Smoking, obesity, and immobilization are established secondary VTE risk factors. 1

Diagnostic Approach

Immediate Neuroimaging

• MRI with MR venography is the gold standard diagnostic test, showing both venous occlusion and parenchymal changes with highest sensitivity. 1, 2

• CT venography is acceptable in emergency settings when MRI is unavailable or contraindicated, though less sensitive for cortical vein thrombosis. 2

• Non-contrast CT has only 30% sensitivity but may show the "empty delta" sign (contrast-enhanced) or hyperdense cortical vein/sinus. 2

• Gradient echo T2 susceptibility-weighted MRI sequences combined with MRV improve diagnostic accuracy over conventional sequences alone. 2

Laboratory Evaluation

Obtain immediately:

• Complete prothrombotic workup: protein C, protein S, antithrombin III, Factor V Leiden, prothrombin G20210A mutation, antiphospholipid antibodies. 1, 5

• Homocysteine level (elevated in 33-99% of CVST cases in some series). 1, 4

• Baseline coagulation studies (aPTT, INR, platelet count) before starting anticoagulation. 6

• Iron studies and complete blood count (iron deficiency anemia with microcytosis is associated with pediatric CVST but relevant in young women). 1

Acute Management Protocol

Anticoagulation: The Critical First Step

Start therapeutic anticoagulation immediately upon diagnosis, even with hemorrhagic transformation present on imaging—this is the single most important intervention. 1, 2, 6

Initial Anticoagulation Options

Low-molecular-weight heparin (LMWH) is preferred over unfractionated heparin:

• Enoxaparin 1.0 mg/kg subcutaneously twice daily OR 1.5 mg/kg once daily. 6
• Dalteparin 200 units/kg subcutaneously once daily. 6

Unfractionated heparin is appropriate when:

• Severe renal failure (creatinine clearance <30 mL/min) is present. 6
• Thrombolytic therapy may be needed. 6
• LMWH is unavailable. 6

Dosing: 5000 IU bolus, then continuous infusion ~30,000 IU over 24 hours, adjusted to maintain aPTT 1.5-2.5 times baseline. 6

Critical Point: Hemorrhage is NOT a Contraindication

• Intracranial hemorrhage occurring as a consequence of CVST is NOT a contraindication to anticoagulation—withholding anticoagulation is a critical error that increases mortality. 1, 2, 6

• The hemorrhage results from venous congestion and backpressure; anticoagulation prevents thrombus propagation and reduces mortality by 108 deaths per 1,000 patients at 90 days. 6

• In clinical trials, no new symptomatic intracranial hemorrhages occurred among anticoagulated patients despite pre-existing hemorrhagic transformation. 6

Discontinue Norethisterone

• It is reasonable to discontinue oral contraceptives (including progestin-only preparations) in adolescents and young women with CVST, given the documented case reports of CVST with norethisterone in the setting of multiple risk factors. 1, 4

Seizure Management

• Seizures occur in approximately 40% of CVST patients (significantly higher than arterial stroke). 2

• Treat seizures aggressively with antiepileptic medications when they occur. 1, 2, 6

• Continuous monitoring for seizure activity should be part of routine care for all CVST patients. 6

Elevated Intracranial Pressure Management

• Consider dexamethasone 4-8 mg/day (oral or IV) ONLY for patients with significant white matter edema causing mass effect, not routinely. 2

• Osmotic diuretics, hyperventilation, and decompressive craniectomy are life-saving interventions in severe cases with brain displacement. 7

Hyperhomocysteinemia Treatment

• Measure serum homocysteine level in all CVST patients. 1

• Institute measures to lower elevated homocysteine: folate supplementation, vitamin B6, vitamin B12, and dietary modification. 1, 4

• This patient should receive vitamin B12, vitamin B6, and folic acid supplementation given documented hyperhomocysteinemia. 4

Monitoring for Deterioration

Serial Neurological Assessment

• Perform neurological examinations every 2-4 hours during the first 24 hours to detect deterioration. 2, 6

• Monitor for worsening consciousness, new focal deficits, seizures, and signs of increased intracranial pressure. 2, 6

• Obtain repeat non-contrast CT at 24-48 hours after starting anticoagulation to assess for hematoma expansion. 6

Escalation Criteria

Consider endovascular therapy (mechanical thrombectomy ± local thrombolysis) when:

• Absolute contraindications to anticoagulation exist. 2, 6
• Progressive neurological decline occurs despite adequate therapeutic anticoagulation. 2, 6
• Rapid clinical deterioration threatens death before systemic anticoagulation can take effect. 6

Consider decompressive hemicraniectomy when:

• Severe mass effect causes progressive neurological deterioration. 2, 6
• Large intracerebral hemorrhage with midline shift is present. 2, 6
• Life-threatening herniation risk exists. 6

Transition to Oral Anticoagulation

Timing and Target

• Start oral anticoagulation early, continuing parenteral anticoagulation for minimum 5 days and until INR ≥2.0 for at least 24 hours. 6

• Target INR 2.0-3.0 (goal 2.5) for vitamin K antagonists (warfarin). 6

Duration of Anticoagulation Based on Etiology

For this patient with multiple prothrombotic factors (PCOS, hyperhomocysteinemia, possible inherited thrombophilia):

• Minimum duration: 3 months for all CVST patients. 2, 6

• If transient/reversible risk factors only (norethisterone use): 3-6 months. 2, 6, 7

• If idiopathic CVST or mild thrombophilia: 6-12 months. 2, 6, 7

• If high-risk inherited thrombophilia (protein C/S deficiency, antithrombin III deficiency, homozygous Factor V Leiden) or recurrent events: consider indefinite anticoagulation. 2, 6, 7

• If severe thrombophilia with recurrent CVST: indefinite anticoagulation is recommended. 6, 7

Follow-Up Imaging

• Obtain CT venography or MR venography at 3-6 months to assess sinus recanalization in stable patients. 2, 6

• The duration of anticoagulation should NOT be determined solely by presence or absence of radiographic recanalization—base decisions on underlying etiology and risk factors. 6

Future Contraceptive Counseling

Absolute Avoidance

• This patient should NEVER use combined oral contraceptives (estrogen-containing), which carry 13-22 fold increased CVST risk. 5

• Third-generation combined contraceptives (desogestrel, gestodene) carry even higher risk than second-generation products. 1, 8

Safer Alternatives

• Hormone-releasing intrauterine devices (IUDs) and progesterone-only pills at contraceptive doses are NOT associated with significant VTE risk increase in most populations. 1

• However, given this patient's documented CVST with norethisterone in the setting of multiple risk factors, even progestin-only methods should be used with extreme caution or avoided. 4, 3

• Non-hormonal contraceptive methods (copper IUD, barrier methods) are safest options for this patient. 3

Common Pitfalls to Avoid

• Do NOT withhold anticoagulation because of hemorrhage on imaging—hemorrhagic venous infarction is an indication FOR, not against, anticoagulation. 6

• Do NOT assume progestin-only preparations are completely safe in women with multiple prothrombotic risk factors—case reports document CVST with norethisterone when risk factors cluster. 4

• Do NOT delay diagnosis because symptoms are nonspecific—median time from symptom onset to diagnosis is 7 days, contributing to worse outcomes. 2

• Do NOT misdiagnose as idiopathic intracranial hypertension—CVST commonly presents with isolated headache and papilledema. 2

• Do NOT base anticoagulation duration solely on imaging recanalization—use underlying etiology and risk factor profile. 6